CAPTRUST Financial Advisors
HIV

CAPTRUST Financial Advisors’s CALYPTE BIOMEDICAL CORP NEW HIV Stock Holding History

CAPTRUST Financial Advisors’s Portfolio HIV Stock Details HIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-33
Closed – – 5381
2022
Q1 		$0 Buy
+33
New – ﹤0.01% 5369
2018
Q3 		– Sell
-33
Closed – – 1788
2018
Q2 		$0 Hold
33
– – ﹤0.01% 1679
2018
Q1 		$0 Buy
+33
New – ﹤0.01% 1439

CAPTRUST Financial Advisors's HIV Position: Q2 2022 in Review

CAPTRUST Financial Advisors sold out of CALYPTE BIOMEDICAL CORP NEW (HIV) in Q2 2022, closing a stake of 33 shares.

CAPTRUST Financial Advisors first reported a position in HIV in Q1 2018 and held it in 3 quarters. The position peaked at $0 in Q1 2022. 0 funds tracked by Wall St. Rank hold HIV as of Q2 2022.

  • CAPTRUST Financial Advisors reported no remaining CALYPTE BIOMEDICAL CORP NEW position as of Q2 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 33 CALYPTE BIOMEDICAL CORP NEW shares in Q2 2022.
  • CAPTRUST Financial Advisors first reported a position in CALYPTE BIOMEDICAL CORP NEW in Q1 2018 and held it in 3 quarters.
  • CAPTRUST Financial Advisors's CALYPTE BIOMEDICAL CORP NEW position peaked at $0 in Q1 2022.
  • 0 funds tracked by Wall St. Rank held CALYPTE BIOMEDICAL CORP NEW as of Q2 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2022, filed 16 Aug 2022.